Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruserud, O.
Right arrow Articles by Huang, T.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruserud, O.
Right arrow Articles by Huang, T.-S.
Stem Cells, Vol. 19, No. 1, 1-11, January 2001
© 2001 AlphaMed Press


CONCISE REVIEW

New Strategies in the Treatment of Acute Myelogenous Leukemia (AML): In Vitro Culture of AML Cells—The Present Use in Experimental Studies and the Possible Importance for Future Therapeutic Approaches

Øystein Bruseruda, Bjørn Tore Gjertsena, Brynjar Fossa, Tien-Sheng Huangb

a Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway;
b Institute of Molecular Biology, The University of Bergen, Bergen, Norway

Key Words. Acute myelogenous leukemia • Experimental models • In vitro culture • Chemotherapy • Apoptosis

Øystein Bruserud, M.D., Medical Department, Haukeland University Hospital, N-5021 Bergen, Norway. Telephone: 47-55-29-80-60; Fax: 47-55-97-29-50; e-mail: oystein.bruserud{at}haukeland.no

In vitro studies of cultured native acute myelogenous leukemia (AML) blasts and cell lines have contributed significantly to our present knowledge about the pathogenesis of AML. In the present article we review different techniques for preparation and in vitro culture of AML blasts. Well-characterized serum-free in vitro conditions can now be used in experimental studies of AML, and this makes comparisons between different studies easier. We also describe assays for characterization of AML progenitor subsets (i.e., suspension cultures, colony assays, long-term in vitro culture, xenotransplantation in immunocompromised mice), and we discuss the possible use of AML cell lines as experimental models in AML. Furthermore, clinical studies suggest that the in vitro growth characteristics of AML blasts assayed by short-term culture of the total native populations can be used as a predictor of prognosis after intensive chemotherapy. These in vitro assays may therefore be used for more accurate identification of prognostic parameters and thereby form a basis for the development of simplified laboratory techniques suitable for routine evaluation of patients undergoing risk-adapted therapy. However, it will be equally important to further evaluate the clinical relevance of assays for primitive AML progenitors, and to develop simplified methods that can be used to characterize these progenitor subsets in the routine clinical evaluation.




This article has been cited by other articles:


Home page
Cancer Res.Home page
L. Li, W. Han, Y. Gu, S. Qiu, Q. Lu, J. Jin, J. Luo, and X. Hu
Honokiol Induces a Necrotic Cell Death through the Mitochondrial Permeability Transition Pore
Cancer Res., May 15, 2007; 67(10): 4894 - 4903.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
O. Bruserud, A. Ryningen, A. M. Olsnes, L. Stordrange, A. M. Oyan, K. H. Kalland, and B. T. Gjertsen
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells
Haematologica, March 1, 2007; 92(3): 332 - 341.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 2001 by AlphaMed Press.